Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 01, 2025 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics Appoints Ryan Richardson to Board of Directors

Autolus announced the appointment of Ryan Richardson to the Company’s Board of Directors.
November 25, 2025 04:00 ET | Source: Autolus Therapeutics plc

NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹

the National Institute for Health and Care Excellence (NICE) has published draft guidance recommending AUCATZYL®.
November 13, 2025 16:05 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

Autolus will present at the Jefferies London Healthcare Conference.
November 12, 2025 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

Autolus announced its operational and financial results for the third quarter ended September 30, 2025
November 03, 2025 09:05 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025

Autolus announced the online publication of five abstracts submitted to the American Society of Hematology (ASH) Annual Meeting.
October 30, 2025 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025

Autolus will report third quarter 2025 financial results and business updates on November 12, 2025.
October 27, 2025 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics Presents Clinical Data Updates at the American College of Rheumatology Convergence 2025

Data from a Phase 1 dose confirmation clinical trial of obe-cel in severe refractory systemic lupus erythematosus will be presented.
October 20, 2025 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics Announces First Patient Dosed in Phase 1 Trial of Obecabtagene Autoleucel (Obe-Cel) in Patients with Progressive Multiple Sclerosis

The first patient has been dosed in the Phase 1 BOBCAT trial of obecabtagene autoleucel (obe-cel) in patients with progressive multiple sclerosis.
October 15, 2025 16:05 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 16, 2025 08:05 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics to Present Clinical Data Update at the American College of Rheumatology (ACR) Convergence 2025

Autolus announces the publication of an abstract submitted to the American College of Rheumatology (ACR) Convergence 2025, to be held October 24-29, 2025.